Additional role for Abiraterone in blocking tumour growth in castration resistant prostate cancer
Saturday, March 16, 2013 - 18:00
in Health & Medicine
As part of an EU-supported IMI-PREDECT consortium (www.predect.eu), a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).